In plain terms

The claim being assessed: Cancer is the re-expression of a coherent, pre-existing ancestral pre-metazoan gene-regulatory program, and that program drives tumorigenesis.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: Preregistered primary SC3 returns Γ. The mandatory paired SC2/SC3 minimum also returns Γ; weakest-link returns Β because SC1/SC4 remain associative, and scope-matched primacy returns Γ. The score concerns the distinctive coherent-program driver, not the proven existence of ancient genes or selected oncogene dependencies.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Cancer cells reuse genes and behaviors shared with ancient organisms. This review asks whether that reuse constitutes a coherent ancestral program that explains cancer, beyond ordinary growth, adaptation and gene regulation.

Implications for health and treatment: Preregistered primary SC3 returns Γ. The mandatory paired SC2/SC3 minimum also returns Γ; weakest-link returns Β because SC1/SC4 remain associative, and scope-matched primacy returns Γ. The score concerns the distinctive coherent-program driver, not the proven existence of ancient genes or selected oncogene dependencies.

Limits for individual care: 59 primary reports with 8 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used complete abstracts/status records and selected original partial-body passages. No complete-paper audit or independent scientific peer review is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 59 primary reports; claims: 64; verified: 64; unverified: 0. Verification is bounded attribution. Access: 8 partial-body and 51 complete abstract/status examinations. Literature cutoff: 2026-10-08; source examination UTC date: 2026-10-08. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 5 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Ancient gene use and regulatory disruption are supported, but an intact pre-existing ancestral program has not been shown to drive cancer; tumor-specific rewiring and metabolic plasticity remain stronger explanations.

Deciding experiment: Preregister an orthology-robust ancestral edge-defined network, then selectively sever its proposed conserved regulatory edges in autochthonous lineage-matched tumors and growth-matched normal tissues, rescue with edge-specific restoration, and track initiation, maintenance and relapse separately.

Belief versus evidence: Preregistered primary SC3 returns Γ. The mandatory paired SC2/SC3 minimum also returns Γ; weakest-link returns Β because SC1/SC4 remain associative, and scope-matched primacy returns Γ. The score concerns the distinctive coherent-program driver, not the proven existence of ancient genes or selected oncogene dependencies.

Best-supported rival: Somatic selection after disrupted multicellular constraints. Lock an ancestral edge-defined network and competing selection/rewiring predictions before measurements; compare growth-matched normal and tumor lineages with selective network disruption and matched rescue while preserving basal replication.

COMPETING MECHANISTIC MODELS

Rank 1: Somatic selection after disrupted multicellular constraints (Ε). Selected regulators and loss of growth constraints cause context-specific tumors and recurrent escape. MYC withdrawal/rechallenge across tissues, KRAS maintenance and bypass, and clonal selection: PMID10488335,12098700,15475948,22541435,24954535,37046096. Conditional transgenes and overlapping investigative lineages limit generality; not a complete unified account of all human initiation.

Rank 2: Forward ecological adaptation (Ε). Tumors remodel regulatory and metabolic states in response to lineage, nutrients and treatment. New UC-MC modules, reversible integrin phenotype, in vivo GOT2 dispensability and respiratory residual states: PMID38685127,9105051,35815941,25119024. Coexpression is not directionality, culture/xenografts are restricted, and the 2014 residual study has incompletely audited 2026 correction.

Rank 3: Proliferation and homology confounding (Δ). Growth and gene-age inference can create part of the apparent ancient-state shift. Growth-matched EGF/KRAS cells and direct methods benchmarks: PMID33811729,25312911,30060201. Bias rebuttal PMID28087778 and some tumor-specific regulatory links remain; not demonstrated that every cancer age signature is artifact.

Rank 4: Coherent ancestral program (Γ). A preserved pre-metazoan regulatory module is re-executed and drives tumors. Phylostratigraphic expression and gene-dependency integration: PMID28484005,30803482. Novel mixed modules, lineage-specific dependencies and missing selective whole-program rescue leave the distinctive causal claim unresolved.

Rank 5: Serial metabolic atavism (Β). Tumors progress through a prescribed sequence of historically older metabolic states. Selected glycolytic/redox and ancient metabolic enrichments: PMID23535601,36499258. Human oxidation, context-matched growth, oxidative residual/CLL/hepatoma states and absent registered longitudinal ordering: PMID26853473,28985563,33811729,28835371,10683245.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Cancer is the re-expression of a coherent, pre-existing ancestral pre-metazoan gene-regulatory program, and that program drives tumorigenesis.

Index names SC2 and SC3 as distinctive gates but its schema permits one primary ID. Register SC3 primacy as the main gate, with mandatory paired SC2/SC3 minimum and weakest-link sensitivities. Ancient-gene expression alone does not prove an executed program. Do not redefine partial atavism after outcomes.

Selection: public-interest rank 33 from the editorial ranking compiled 2026-09-23; categorical prior verdicts were visible. Private fresh review; earlier documents are preserved.

Evidence and causal interpretation

Evolutionary reuse is well supported, but the registered hypothesis makes a stronger claim: a coherent pre-existing pre-metazoan regulatory program must be identified and shown to drive tumors. Gene age, conserved metabolism and dedifferentiation do not by themselves identify that network.

The 2017 seven-type TCGA study reports 3473 tumors, 386 normals and 17318 aged genes; many UC processes rise but others do not, and ancient-process coregulation is already substantial in normal tissue (PMID28484005). The 2019 analysis relates mutation/CNA groups to directed reference networks and genuine CRISPR dependencies across 364 cell lines (PMID30803482). Calling these papers devoid of perturbation information would be wrong; calling them a selective coherent-program rescue would also be wrong.

The 2024 study uses 31 cancer types and 16 matched-normal cohorts for novelty comparisons. New mixed UC-MC modules, associations with copy-number change and heterogeneity favor tumor-specific rewiring (PMID38685127). WGCNA coexpression does not establish directed regulatory causality, and grade/stage contrasts do not observe individual evolutionary histories. These studies share TCGA and gene-age assignments, so their counts do not represent independent biological causal replications.

Homology-detection biases and their rebuttal are both retained (PMID25312911,28637261,28087778,30060201). Growth-matched EGF/KRAS experiments show that most metabolic shifts can follow proliferation, while some genuine regulator-specific differences remain (PMID33811729). This comparator does not prove all cancer transcriptome-age patterns are artifacts; it specifies a missing growth-matched control.

MYC withdrawal produces regression across several conditional tissues, but outcomes differ: osteosarcoma differentiation can persist whereas liver cells retain reversible dormancy and islet/skin tumors may recur (PMID10488335,12098700,15475948,15613240). KRAS pancreatic maintenance and YAP bypass add distinct selected dependencies (PMID22541435,24954535). These results are compatible with selection and regulatory plasticity; they do not logically exclude necessary downstream ancient modules, but they do not identify a common recovered program.

Microenvironmental reversion is also causal in selected models: integrin-blocking antibodies and Fab fragments restore breast 3D organization, washout restores malignant behavior and brief pretreatment lowers xenograft nodules (PMID9105051). The reversible contrast argues against contamination by a benign clone. It establishes tissue-context influence in one model, not universal genotype independence.

Human NSCLC isotope infusions show retained glucose oxidation and heterogeneity (PMID26853473). Positional NMR and relative TCA modeling go beyond simple label presence but do not quantify absolute ATP partition. Lactate tracing and MCT1 deletion identify a substrate uptake route (PMID28985563), while culture doubling time persists after transporter loss. Uptake identity and growth necessity remain separate.

After KRAS withdrawal, some residual pancreatic cells exhibit respiratory dependence and oligomycin-sensitive relapse behavior (PMID25119024); the small arm and incompletely examined 2026 correction prevent treating it as sole decisive proof. GOT2 dependence disappears between culture and in vivo settings (PMID35815941), and pediatric/breast/CLL/hepatoma findings retain substantial metabolic diversity. A fixed serial evolutionary regression has not been prospectively tested in this corpus.

Current source notices matter. The 1999 defined-transformation report has an April 2026 Expression of Concern about potential duplicated gel bands with unavailable raw data, while editors retain support from other results; it is neither retracted nor used here as load-bearing positive evidence. The YAP correction replaces one GFP image with independently quantified graphs reportedly unchanged, and TRACERx corrects swapped death/censor symbols. Other unavailable correction details remain explicit limits.

The nominal driver stays Γ under the preregistered SC3 gate and paired SC2/SC3 sensitivity. Weakest-link Β reflects the weaker expression and serial-metabolism components. A broader use of atavism to mean any lost multicellular constraint is compatible with many results, but it would replace the distinctive coherent-program claim after observing outcomes.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. Preregistered primary SC3 returns Γ. The mandatory paired SC2/SC3 minimum also returns Γ; weakest-link returns Β because SC1/SC4 remain associative, and scope-matched primacy returns Γ. The score concerns the distinctive coherent-program driver, not the proven existence of ancient genes or selected oncogene dependencies. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[2] Thirty solid cancer types connect mutation/CNA strata to UC-MC regulatory links; 364 Avana cell-line CRISPR screens and 250-drug data inform dependency/response associations. There is genuine single-gene perturbation data, but no selective unified ancestral network subtraction/rescue or endogenous in vivo program dependency; pooled regulator contrasts are not randomized installation.

[6] Simulations show homology-detection error can bias inferred gene ages and expression-age trends. Synthetic detection bias does not show all cancer age patterns are artifacts; linked erratum PMID27738272 details were not accessible for examination.

[7] Further simulations and empirical-method assessment identify systematic phylostratigraphic errors. A disputed methodological result is not direct tumor causality evidence; robustness should be tested on the actual cancer gene sets.

[8] Reanalysis argues reported patterns withstand estimated BLAST false-negative rates of 11–15 percent. Methodological rebuttal is retained; persistence of a trend does not establish an ancestral driver, and cancer-specific proliferation controls are separate.

[9] Alternative homology tools and error-prediction benchmarks fail to eliminate age-estimation bias; removal can erase or reverse tested trends. Results concern tested benchmarks, not a definitive refutation of every tumor phylostratigraphic association.

[11] SV40 elements disrupting pRB, p53 and PP2A cooperate with telomerase/RAS in human transformation. Engineered viral/cell-line model and shared Hahn platform; linked erratum has no supplied PMID and unexamined details. Constraint disruption does not distinguish flexible partial atavism by itself.

[12] Stepwise p53/INK4A/RAS/hTERT manipulations produce transformation-associated expression shifts. Installed elements and signatures do not isolate an ancestral network; engineered fibroblasts cannot establish general human initiation.

[13] Conditional K-RASG12D expression induces tumors in basal epithelium within 10–20 days. Forced expression proves regulator capability in that tissue, not the absence of all downstream evolutionary reuse.

[14] Defined elements transform FTSEC, including viral-free p53/CDK4/PP2A changes with hTERT/MYC. Cultured/xenografted installation is bounded; does not reconstruct or subtract a coherent ancestral program.

[15] PAX3-FOXO1/MYCN supports tumor initiation/maintenance; withdrawal regresses tumors but some recur fusion independently. Immortalized xenograft context; recurrence demonstrates plasticity rather than universal addiction or a universal ancestral route.

[16] Switching MYC off regresses hematopoietic tumors with apoptosis/differentiation. Conditional transgene model; MYC necessity here does not logically exclude a required downstream ancestral module.

[17] Brief MYC inactivation permits sustained differentiation; reactivation induces apoptosis in this model. Tissue-specific response differs from other MYC systems; no whole ancestral-network test.

[18] MYC withdrawal produces differentiated dormant tumor-derived liver/biliary cells; reactivation restores tumors. Dormancy and reactivation differ from irreversible osteosarcoma reversion; conditional model not broad human primacy.

[19] Brief MYC shutdown is insufficient for durable islet/skin reversion, with recurrence influenced by Bcl-xL/context. A context boundary for regulator dependence, not proof of a single ancient fallback route.

[20] MYC-transgene withdrawal regresses lymphoma; genomic instability and transgene-related selection accompany recurrence. Related MYC platforms are not independent biological replications for each paper; selection does not prove program ancestry.

[21] Recurrent tumors restore MYC signaling through tTA mutation/endogenous MYC/Notch, with MYC knockdown dependency. Restoration through alternative routes supports selected dependency, not universal MYC necessity or ancestral-program independence.

[22] KRAS maintains pancreatic tumors and controls anabolic glucose/nonoxidative PPP use. Conditional oncogene setting; metabolic reprogramming is not a measured evolutionary sequence.

[23] After KRAS withdrawal, residual cells show respiratory dependence, poor glycolytic compensation and oligomycin-sensitive sphere/regrowth readouts; one of four treated animals remained relapse-free beyond 60 days. Selected model, pleiotropic drug and small in vivo arm; correction PMID41951747 (2026) lists corrected Fig 4a but full notice was unavailable. Not load-bearing alone or fully current figure audit.

[24] YAP1/TEAD2/E2F can bypass KRAS dependence in recurrent pancreatic tumors. 2019 correction PMID31730860 replaces a wrong GFP image in Fig 4C; independent quantified graphs reportedly unchanged. Shared inducible platform and corrected image limit independence.

[25] KRAS ablation kills whereas MEK inhibition is cytostatic; RTK/PI3K compensation motivates combinations. Genetic removal and incomplete downstream pharmacology differ; effects do not establish ancestor-network necessity.

[26] KRAS-associated GOT1 glutamine/redox pathway supports cultured growth and tumor assays. Culture/environment and redox pleiotropy; linked erratum details unavailable. Do not treat as universal metabolic dependency.

[27] GOT2 loss impairs cultured redox/growth but does not impair tested xenograft/autochthonous tumors; CAF pyruvate rescues culture. In vivo failure of pyruvate blocking to sensitize shows additional compensation; null is context-specific, not no metabolic causality.

[28] KRAS/MAPK/MYC regulates RPIA and nucleotide PPP; intervention affects differential KRAS-sensitive/resistant growth. Pathway-specific selected dependencies do not imply ordered historical metabolic regression.

[30] Thirty glucose/five lactate-infused lung-cancer patients show lactate oxidation; MCT1 deletion removes lactate labeling in HCC15 xenografts. Model cannot quantitatively determine net lactate flow; labeled lactate enters other pools. MCT1 knockout preserves culture doubling time: substrate uptake is not demonstrated growth necessity.

[31] IACS complex-I inhibition reduces glucose/lactate TCA contributions and increases glutamine; yeast NDI1 NADH-oxidation rescue normalizes relevant labeling. TCA labeling alone does not measure ETC before perturbation; selective model rescue does not establish a universal tumor respiratory fraction.

[34] RAS-driven lung tumors require pyruvate oxidation in vivo and use less glutamine than cultured counterparts. Model-specific endogenous dependence and culture mismatch; not a universal lung/metastatic metabolism claim.

[35] EGF-versus-KRASG12V proliferation matching explains most metabolic shifts in immortalized 184A1 cells; several KRAS-associated fluxes are lower at matched growth. Growth matching is a useful rival control, not direct validation of all TCGA gene-age associations or intact normal tissue physiology.

[36] PDH activation limits growth through NADH accumulation; uncoupling/ATP hydrolysis can restore NAD balance and proliferation. Aerobic glycolysis can serve redox demands rather than respiratory absence; culture manipulations do not establish whole-tumor universality.

[39] ERBB2/EGFR/PI3K restores detached-cell glucose/PPP support; antioxidant rescue enables fatty-acid oxidation without restoring glucose uptake. Context/pleiotropy and culture assays; survival rescue is not coherent ancient-program reconstitution.

[40] Function-blocking beta1-integrin antibodies/Fab revert malignant 3D phenotypes; washout restores malignancy, and brief pretreatment lowers xenograft nodules. Reversible single-line tissue signaling context; not universal genotype independence or reversion of all malignancy.

[41] Brief compression yields more normal acini with NO-dependent response. Physical context and selected 3D readouts, not endogenous in vivo cancer eradication or ancestry-specific perturbation.

[42] cAMP/PI3K/fibronectin interventions alter malignant organization and chromatin accessibility. Related HMT model platform; pleiotropic reversion does not establish restoration of an intact ancestral or metazoan network.

[44] SOX9 boosts proliferation without hyperplasia alone, enhances Pten-associated PIN and is attenuated by knockout. A metazoan developmental pathway can contribute without sufficiency; context-specific genetic interaction.

[47] Hand2 loss affects mesothelial development; reactivation is observed in mesothelioma. Developmental loss-of-function is not tumor Hand2 necessity, and reactivation is of a later multicellular program.

[48] SOX11/4 embryonic-state induction and knockout influence normal repair through targets including fascin. Physiological embryonic reuse can occur without cancer; normal repair comparator is not tumor-program disproof.

[54] MCT1 perturbation reduces metastasis without equivalent primary-growth effects; antioxidants rescue selected readouts. Relapse/metastatic metabolism differs from primary growth and culture uptake; transplantation context limits generality.

[55] Stem-like cells show greater oxidative capacity and less lactate than differentiated counterparts; irradiation alters states. Marker/culture selection does not establish a stable endogenous hierarchy or ordered backward evolution.

[56] AS30D hepatoma respiration/oligomycin analyses estimate predominantly oxidative ATP production. Single cell model and ATP estimation assumptions; does not quantify all human cancers.

[57] Quiescent glioma stem-like populations have low glycolytic and oxidative rates with metabolic heterogeneity after irradiation. Cultured selection and state-specific output, not generalized tumor-wide respiratory failure or a serial evolutionary order.

[58] HDAC inhibition lowers MYC and raises PGC1/PPAR-linked FAO/OXPHOS; combined FAO/HDAC intervention improves tested tumor-model survival. Drug pleiotropy and selected settings; induced forward adaptation fits metabolic plasticity without ancestry-specific identification.

[59] 45-patient CLL cohort shows variable respiration linked to prognosis; BCR/PI3K perturbation reduces OCR and ECAR. Ex vivo signaling and association do not establish universal respiratory dependency or evolutionary ordering.

Tally: 41 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Shared cohorts, experimental platforms, transgenic lineages and repeated outcomes do not constitute fully independent causal lines.

Cap audit, precedence and Β/Γ/Δ boundary

The 02 cancer rubric governs the driver and generalization burdens; 03 secondary guidance cautions that chromatin/expression states are not regulatory causation. True MYC/KRAS genetic dependencies and individual CRISPR phenotypes are retained at their own scope. Their convergence does not identify the ancestry-specific network required by SC2/SC3, so the assembled set still lacks the distinctive experiment.

Gamma hard-rule audit: Bulk network ages, coexpression and individual CRISPR dependencies do not establish an executed whole ancestral program. In vitro or transplant specificity and forced regulator dependence cannot be transferred to coherent-program primacy in endogenous cancer.

SC1 cap: “Association-only cancer claims cap at Β.” Β: ancient-expression and coexpression patterns are human associations, with a real methods debate and incomplete matched-normal proliferation controls.

SC2 cap: “Mechanistically plausible cell culture or transplantation-linked models without endogenous in vivo dependency cap at Γ.” Γ: network/mutation/dependency integration supplies mechanistic plausibility and culture perturbations, but not recovery, selective subtraction or rescue of a predeclared coherent ancestral program. New mixed modules favor rewiring.

SC3 cap: “Mechanistically plausible cell culture or transplantation-linked models without endogenous in vivo dependency cap at Γ.” Γ: functional regulator and metabolic dependencies exist, but no program-specific endogenous in vivo initiation/maintenance/relapse dependence establishes the nominal driver.

SC4 cap: “Association-only cancer claims cap at Β.” Β: metabolic state associations are heterogeneous; retained oxidation and treatment-selected respiratory states constrain serial regression, and no registered longitudinal evolutionary order was tested.

SC1 field-valid definition: “ - Endogenous genetic manipulation in autochthonous models - Patient-derived system perturbation with matched rescue AND in vivo confirmation - Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: no. Β: ancient-expression and coexpression patterns are human associations, with a real methods debate and incomplete matched-normal proliferation controls.

SC2 field-valid definition: “ - Endogenous genetic manipulation in autochthonous models - Patient-derived system perturbation with matched rescue AND in vivo confirmation - Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: no. Γ: network/mutation/dependency integration supplies mechanistic plausibility and culture perturbations, but not recovery, selective subtraction or rescue of a predeclared coherent ancestral program. New mixed modules favor rewiring.

SC3 field-valid definition: “ - Endogenous genetic manipulation in autochthonous models - Patient-derived system perturbation with matched rescue AND in vivo confirmation - Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: no. Γ: functional regulator and metabolic dependencies exist, but no program-specific endogenous in vivo initiation/maintenance/relapse dependence establishes the nominal driver.

SC4 field-valid definition: “ - Endogenous genetic manipulation in autochthonous models - Patient-derived system perturbation with matched rescue AND in vivo confirmation - Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: no. Β: metabolic state associations are heterogeneous; retained oxidation and treatment-selected respiratory states constrain serial regression, and no registered longitudinal evolutionary order was tested.

Upward threshold ladder

SC1 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: no. A prespecified causal test matching this subclaim, with mechanistic engagement, meaningful phenotype change and an appropriate negative control.

SC2 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: no. A prespecified causal test matching this subclaim, with mechanistic engagement, meaningful phenotype change and an appropriate negative control.

SC3 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: no. A prespecified causal test matching this subclaim, with mechanistic engagement, meaningful phenotype change and an appropriate negative control.

SC4 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: no. A prespecified causal test matching this subclaim, with mechanistic engagement, meaningful phenotype change and an appropriate negative control.

Upper ladder: Endogenous genetic network perturbation, somatic natural experiments, longitudinal clonal dependency, selective rescue and independent cancer-lineage replication are live upper-level equivalents. They need not be RCTs, but none here establishes the distinctive ancestry-defined coherent program.

Independence: Trigos studies share gene-age assignments, TCGA samples and investigators; 2023 preprint/2024 article are one report. MYC and KRAS papers reuse model platforms. Growth matching, homology simulations and human isotope assays exclude different errors but are not independent demonstrations of the nominal ancestral program.

Falsification and pitfalls

Proposed metabolic dependency disappears in physiologic tumor context. GOT2 loss impairs culture but not tested in vivo tumors, PMID35815941. Additional downgrade: False.

Rigid metabolic regression conflicts with retained/adaptive oxidation. Human isotope and residual-cell results PMID26853473,28985563,25119024. Additional downgrade: False.

Gene ancestry equated with regulatory-program ancestry. Protein conservation and coexpression do not reconstruct ancestral regulatory edges.

No program rescue misreported as no perturbation evidence. Trigos 2019 incorporates genuine single-gene CRISPR screens.

Inferred grade order equated with prospective tumor history. Cross-sectional TCGA classes do not trace an individual LGG-to-GBM trajectory.

Isotope labels equated with absolute ATP/ETC flux. Relative enrichment, recirculation and model identifiability retained.

Source integrity notices silently ignored. 1999 EOC and 2014/2019/2024 corrections separately reconciled.

Adversarial steelman: above, then below

Steelman Δ: UC-MC hubs have mutations, dependency screens and drug-response associations; disabling oncogenes or metabolism changes cancer phenotype. The missing discriminator is whether a coherent ancestral program, rather than these individual indispensable processes, was selectively perturbed.

Steelman Β: no intact ancestral network has been measured or rescued, and main human evidence is associative. Γ is retained because integrated dependency data and specific mechanistic culture/model evidence add plausible links, while the paired gate and weaker association sensitivities are explicit.

Retain Γ with Moderate confidence; do not promote generic conserved-gene necessity to ancestral-program causality. Weakest-link Β is disclosed, not suppressed.

Final score, causal direction and M/S/D

Preregistered primary SC3 returns Γ. The mandatory paired SC2/SC3 minimum also returns Γ; weakest-link returns Β because SC1/SC4 remain associative, and scope-matched primacy returns Γ. The score concerns the distinctive coherent-program driver, not the proven existence of ancient genes or selected oncogene dependencies.

Step 2: no directional causal dependency is demonstrated for the nominal coherent ancestral program. This records unestablished program causation, not biological inertness of conserved genes; specific regulators and metabolic pathways can be causal.

Momentum: Mechanistic only. 2024 mixed-module mapping, 2022 GOT2 context tests and 2026 linked correction notices sharpen the boundary, but all are published mechanistic or source-integrity work and no running experiment that could cross the next threshold is named; no ongoing recruiting trial is asserted. Momentum modifies no letter.

Stability: Stable. No named pending result is asserted to be likely to move the registered score imminently.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Preregister an orthology-robust ancestral edge-defined network, then selectively sever its proposed conserved regulatory edges in autochthonous lineage-matched tumors and growth-matched normal tissues, rescue with edge-specific restoration, and track initiation, maintenance and relapse separately.

Readout: Single-cell ancestry-aware edge activity, clonal tumor burden/relapse, growth and viability with metabolic flux and target engagement. Controls: Comparable basal replication, normal proliferating lineage, matched nonancestral edges, off-target resistant rescue and alternative rewiring predictions. Supporting: Selective ancestral-network loss consistently removes tumor dependency and matched restoration rescues without simply restoring generic proliferation. Falsifying: Tumors persist after confirmed network interruption, normal proliferating cells fail equally, or new context-dependent edges better predict response.

RESEARCH TIMELINE

KNOWLEDGE GAPS

Define the ancestral network by conserved regulatory edges before tumor outcomes, rather than equating old proteins with a recovered program.

Recompute gene ages with orthology/detection-error robustness and matched proliferating normal lineages.

Use single-cell lineage/composition controls so bulk normal differentiation loss is separated from UC activation.

Separate single-gene essentiality from coherent program-selective loss and matched rescue preserving basal proliferation.

Prospectively test ordered serial metabolism with identifiable flux/ATP models; cross-sectional states are not chronological regressions.

Map residual, metastatic and treatment-selected oxidation without redefining the historical sequence after observing it.

Replicate distinctive network perturbation across independent tumor contexts with initiation, maintenance and relapse endpoints.

Complete current correction/figure audits, including unavailable details of the 2026 residual-cell correction, before reusing those figures publicly.

METHODS AND CONSENSUS CONTRIBUTION

Consensus was used through the signed-in browser for discovery, counterevidence, research-gap and timeline suggestions, and attempted checks of specific indexed full-text passages. Returned Methods/Results passages were reconciled with original-paper passages where available; failed retrievals, source substitutions and unverified aspects are recorded in the case reconciliation. Successful passage checks are distinguished from provider summaries. Provider screening counts, citation counts and meters were not used as primary counts or HSEF scores. This source log records access depth; it does not claim complete-paper or supplement review. The monthly API allowance was conserved: zero Consensus API calls in this batch.

REVIEWER NOTES

59 primary reports examined with eight partial original-body examinations; methods, normal-repair and metabolic comparators are explicitly identified. Theory, commentary, duplicate preprints and the narrative PMID34364910 are excluded from primary count. The 1999 report PMID10440377, which carries the 2026 Editorial Expression of Concern PMID41986727, is retained as examined historical context, not positive load-bearing proof. No complete-paper/supplement or blinded calibration claim.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1 (HSEF v5.3 pipeline). Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Relation to the earlier edition. This is the 2026-10-09 revised edition of the review first issued in deliverables/hsef_v53_popularity_ranks_31_35_2026-10-08/cancer-atavism/. A full diff against that edition shows the revision added exactly one block — the "Consensus provenance reconciliation" section — and changed nothing else: no letter, confidence, role, subclaim, count, reference or evidence card differs. No earlier adversarial approval of this case exists anywhere in the deliverables tree, so the present section is its first adversarial adjudication.

Scope of checks. All 59 REFERENCES PMIDs were re-verified against PubMed metadata: 59/59 resolve to the stated title, first author, journal and year, and 59/59 printed DOI strings match the PubMed DOI field exactly. No reference is retracted, and no reference has a consortium first author. The one integrity notice in the package was confirmed directly: PMID 41986727 is a real Editorial Expression of Concern in Nature 652(8112):E18, April 2026, attached to Hahn 1999 (PMID 10440377), and the review's treatment of that source as examined historical context rather than load-bearing positive evidence is correct. Nine load-bearing claims were checked against the original abstracts: the 2017 phylostratigraphy study (TCGA solid tumours, unicellular-conserved genes up-regulated and metazoan-origin genes inactivated, coordinated expression lost in tumours, twelve highly connected mediating genes); the 2019 network study (point mutations enriched in regulators linking unicellular and multicellular subnetworks, copy-number alterations affecting downstream targets); the 2024 co-expression study (31 tumour types, the largest tumour-normal differences inside mixed UC-MC modules, rewiring increasing with grade and stage, enrichment for amplifications); the growth-matched EGF/KRAS experiment (most metabolic phenotypes in KRAS-expressing cells similar to EGF-stimulated controls at comparable growth rates); MYC withdrawal across conditional tissues with divergent outcomes; KRAS maintenance and YAP1 bypass; integrin-blocking reversion with washout restoring malignant behaviour; human NSCLC isotope infusion showing retained glucose oxidation; and the lactate/MCT1 tracing result. All nine were supported as stated.

Rejected findings (checked, no change).

1. Aggregation. The index names SC2 and SC3 as distinctive gates while the schema permits one primary ID; the review registers SC3 primacy with a mandatory paired SC2/SC3 minimum and reports all three alternatives (weakest-link Β, primary-subclaim Γ, scope-matched Γ). The Β sensitivity is driven by SC1 and SC4, which are narrower expression and serial-metabolism components reported separately, so the headline is not being set by a narrower subclaim. The deviation from the index wording is disclosed in the registered-claim section. No change.
2. Β/Γ boundary for the nominal. The distinctive claim is a coherent pre-existing pre-metazoan program that drives tumours. Phylostratigraphic expression and dependency integration give simplified-system and network support without a selective whole-program disruption-and-rescue experiment, which is Γ. Raising it would require that missing experiment; lowering it to Β would discard genuine perturbation content in the cited work.
3. Causal role. "epiphenomenon" at framework Step 2 is correct for the distinctive coherent-program account: no study shows the proposed program driving tumours, and none shows the reverse either.
4. Competing models ranked at Ε and Δ above the nominal Γ. Permitted; the tournament does not set the nominal's level and the review states so.
5. The "Best-supported rival" line. Checked against the scorecard: models_evaluated[0] is rank 1 with is_nominal false, and the nominal ("Coherent ancestral program") is rank 4, so the renderer defect that prints the nominal as its own rival does not occur here.
6. The preserved consensus statement. The METHODS AND CONSENSUS CONTRIBUTION section records signed-in Consensus browser use for discovery and attempted indexed full-text checks, so it does not contradict the spliced provenance block. Nothing was scoped or deleted there.
7. Three evidence cards record "ErratumIn: PMID not supplied". The correction identifiers for those sources are genuinely absent from the retrieved metadata, and the review says what each correction changed without asserting an identifier. Retained as a residual limitation.
8. Print/issue year versus e-pub year. No reference differs by more than the accepted plus or minus one year.
9. Validator warning v5.claim_form ("entry_form is 'phenomenon'"). The registered claim states a presence - re-expression of a coherent ancestral program - plus its consequence, that the program drives tumorigenesis, which is the documented exception. Rejected.

Residual limitations. Eight sources were examined at partial-body depth and 51 at abstract/status depth, so figures taken from full text (3473 tumours, 386 normals and 17318 age-assigned genes in the 2017 study; 364 CRISPR cell lines in the 2019 study; 16 matched-normal cohorts in the 2024 study) rest on the package's own retrieval receipts. The bodies of the 2014, 2019, 2024 and 2026 correction notices were not read, so the review's refusal to characterise them beyond the published notice text is retained. The scorecard and provenance header name the generating system "Codex"; this adversarial review does not alter package-level provenance strings. A divergent copy of this slug at deliverables/hsef_v53_popularity_ranks_31_35_2026-10-08/cancer-atavism/ was deliberately not modified.

Validator. The frozen HSEF v5.3 validator was re-run on the revised scorecard and prose: 33 pass, 1 warn, 1 fail. All v5.3 checks pass, including level.glyph, level.descriptor, logic.aggregation, logic.cap_ceiling, logic.boundary_gamma, v5.ledger (59 sources / 64 claims), v5.provenance and quality.msd_default. The warning is v5.claim_form, rejected above by standing convention. The failure is v5.lay_summary, which the validator itself marks "mandatory from v5.4" and which therefore does not apply to this v5.3 package. Full output is in validator.txt.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. - Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Trigos AS, Pearson RB, Papenfuss AT et al. Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 2017. PMID 28484005. DOI: 10.1073/pnas.1617743114. Access: full_text_partial. Study: PMID28484005.

2. Trigos AS, Pearson RB, Papenfuss AT et al. Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer. eLife. 2019. PMID 30803482. DOI: 10.7554/eLife.40947. Access: full_text_partial. Study: PMID30803482.

3. Trigos AS, Bongiovanni F, Zhang Y et al. Disruption of metazoan gene regulatory networks in cancer alters the balance of co-expression between genes of unicellular and multicellular origins. Genome biology. 2024. PMID 38685127. DOI: 10.1186/s13059-024-03247-1. Access: full_text_partial. Study: PMID38685127.

4. Fernandes J, Guedes PG, Lage CL et al. Tumor malignancy is engaged to prokaryotic homolog toolbox. Medical hypotheses. 2012. PMID 22285198. DOI: 10.1016/j.mehy.2011.12.014. Access: abstract_metadata. Study: PMID22285198.

5. Vainshelbaum NM, Giuliani A, Salmina K et al. The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction. International journal of molecular sciences. 2022. PMID 36499258. DOI: 10.3390/ijms232314930. Access: abstract_metadata. Study: PMID36499258.

6. Moyers BA, Zhang J et al. Phylostratigraphic bias creates spurious patterns of genome evolution. Molecular biology and evolution. 2015. PMID 25312911. DOI: 10.1093/molbev/msu286. Access: abstract_metadata. Study: PMID25312911.

7. Moyers BA, Zhang J et al. Further Simulations and Analyses Demonstrate Open Problems of Phylostratigraphy. Genome biology and evolution. 2017. PMID 28637261. DOI: 10.1093/gbe/evx109. Access: abstract_metadata. Study: PMID28637261.

8. Domazet-Lošo T, Carvunis AR, Albà MM et al. No Evidence for Phylostratigraphic Bias Impacting Inferences on Patterns of Gene Emergence and Evolution. Molecular biology and evolution. 2017. PMID 28087778. DOI: 10.1093/molbev/msw284. Access: abstract_metadata. Study: PMID28087778.

9. Moyers BA, Zhang J et al. Toward Reducing Phylostratigraphic Errors and Biases. Genome biology and evolution. 2018. PMID 30060201. DOI: 10.1093/gbe/evy161. Access: abstract_metadata. Study: PMID30060201.

10. Hahn WC, Counter CM, Lundberg AS et al. Creation of human tumour cells with defined genetic elements. Nature. 1999. PMID 10440377. DOI: 10.1038/22780. Access: abstract_metadata. Study: PMID10440377.

11. Hahn WC, Dessain SK, Brooks MW et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Molecular and cellular biology. 2002. PMID 11884599. DOI: 10.1128/MCB.22.7.2111-2123.2002. Access: abstract_metadata. Study: PMID11884599.

12. Milyavsky M, Tabach Y, Shats I et al. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer research. 2005. PMID 15930270. DOI: 10.1158/0008-5472.CAN-04-3880. Access: abstract_metadata. Study: PMID15930270.

13. Vitale-Cross L, Amornphimoltham P, Fisher G et al. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer research. 2004. PMID 15604235. DOI: 10.1158/0008-5472.CAN-04-2623. Access: abstract_metadata. Study: PMID15604235.

14. Karst AM, Levanon K, Drapkin R et al. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proceedings of the National Academy of Sciences of the United States of America. 2011. PMID 21502498. DOI: 10.1073/pnas.1017300108. Access: abstract_metadata. Study: PMID21502498.

15. Pandey PR, Chatterjee B, Olanich ME et al. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. The Journal of pathology. 2017. PMID 28138962. DOI: 10.1002/path.4867. Access: abstract_metadata. Study: PMID28138962.

16. Felsher DW, Bishop JM et al. Reversible tumorigenesis by MYC in hematopoietic lineages. Molecular cell. 1999. PMID 10488335. DOI: 10.1016/s1097-2765(00)80367-6. Access: abstract_metadata. Study: PMID10488335.

17. Jain M, Arvanitis C, Chu K et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (New York, N.Y.). 2002. PMID 12098700. DOI: 10.1126/science.1071489. Access: abstract_metadata. Study: PMID12098700.

18. Shachaf CM, Kopelman AM, Arvanitis C et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004. PMID 15475948. DOI: 10.1038/nature03043. Access: abstract_metadata. Study: PMID15475948.

19. Pelengaris S, Abouna S, Cheung L et al. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis. BMC biology. 2004. PMID 15613240. DOI: 10.1186/1741-7007-2-26. Access: abstract_metadata. Study: PMID15613240.

20. Marinkovic D, Marinkovic T, Mahr B et al. Reversible lymphomagenesis in conditionally c-MYC expressing mice. International journal of cancer. 2004. PMID 15095297. DOI: 10.1002/ijc.20099. Access: abstract_metadata. Study: PMID15095297.

21. Choi PS, van Riggelen J, Gentles AJ et al. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proceedings of the National Academy of Sciences of the United States of America. 2011. PMID 21969595. DOI: 10.1073/pnas.1107303108. Access: abstract_metadata. Study: PMID21969595.

22. Ying H, Kimmelman AC, Lyssiotis CA et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012. PMID 22541435. DOI: 10.1016/j.cell.2012.01.058. Access: abstract_metadata. Study: PMID22541435.

23. Viale A, Pettazzoni P, Lyssiotis CA et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014. PMID 25119024. DOI: 10.1038/nature13611. Access: full_text_partial. Study: PMID25119024.

24. Kapoor A, Yao W, Ying H et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014. PMID 24954535. DOI: 10.1016/j.cell.2014.06.003. Access: abstract_metadata. Study: PMID24954535.

25. Pettazzoni P, Viale A, Shah P et al. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer research. 2015. PMID 25736685. DOI: 10.1158/0008-5472.CAN-14-1854. Access: abstract_metadata. Study: PMID25736685.

26. Son J, Lyssiotis CA, Ying H et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013. PMID 23535601. DOI: 10.1038/nature12040. Access: abstract_metadata. Study: PMID23535601.

27. Kerk SA, Lin L, Myers AL et al. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. eLife. 2022. PMID 35815941. DOI: 10.7554/eLife.73245. Access: abstract_metadata. Study: PMID35815941.

28. Santana-Codina N, Roeth AA, Zhang Y et al. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nature communications. 2018. PMID 30470748. DOI: 10.1038/s41467-018-07472-8. Access: abstract_metadata. Study: PMID30470748.

29. Hensley CT, Faubert B, Yuan Q et al. Metabolic Heterogeneity in Human Lung Tumors. Cell. 2016. PMID 26853473. DOI: 10.1016/j.cell.2015.12.034. Access: full_text_partial. Study: PMID26853473.

30. Faubert B, Li KY, Cai L et al. Lactate Metabolism in Human Lung Tumors. Cell. 2017. PMID 28985563. DOI: 10.1016/j.cell.2017.09.019. Access: full_text_partial. Study: PMID28985563.

31. Pachnis P, Wu Z, Faubert B et al. In vivo isotope tracing reveals a requirement for the electron transport chain in glucose and glutamine metabolism by tumors. Science advances. 2022. PMID 36044570. DOI: 10.1126/sciadv.abn9550. Access: abstract_metadata. Study: PMID36044570.

32. Johnston K, Pachnis P, Tasdogan A et al. Isotope tracing reveals glycolysis and oxidative metabolism in childhood tumors of multiple histologies. Med (New York, N.Y.). 2021. PMID 33860280. DOI: 10.1016/j.medj.2021.01.002. Access: abstract_metadata. Study: PMID33860280.

33. Kernstine KH, Faubert B, Do QN et al. Does Tumor FDG-PET Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer? The Annals of thoracic surgery. 2020. PMID 31846640. DOI: 10.1016/j.athoracsur.2019.10.061. Access: abstract_metadata. Study: PMID31846640.

34. Davidson SM, Papagiannakopoulos T, Olenchock BA et al. Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. Cell metabolism. 2016. PMID 26853747. DOI: 10.1016/j.cmet.2016.01.007. Access: abstract_metadata. Study: PMID26853747.

35. Keibler MA, Dong W, Korthauer KD et al. Differential substrate use in EGF- and oncogenic KRAS-stimulated human mammary epithelial cells. The FEBS journal. 2021. PMID 33811729. DOI: 10.1111/febs.15858. Access: full_text_partial. Study: PMID33811729.

36. Luengo A, Li Z, Gui DY et al. Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Molecular cell. 2021. PMID 33382985. DOI: 10.1016/j.molcel.2020.12.012. Access: abstract_metadata. Study: PMID33382985.

37. Ghergurovich JM, Lang JD, Levin MK et al. Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer. Med (New York, N.Y.). 2021. PMID 34223403. DOI: 10.1016/j.medj.2021.03.009. Access: abstract_metadata. Study: PMID34223403.

38. Dolfi SC, Chan LL, Qiu J et al. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer & metabolism. 2013. PMID 24279929. DOI: 10.1186/2049-3002-1-20. Access: abstract_metadata. Study: PMID24279929.

39. Schafer ZT, Grassian AR, Song L et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature. 2009. PMID 19693011. DOI: 10.1038/nature08268. Access: abstract_metadata. Study: PMID19693011.

40. Weaver VM, Petersen OW, Wang F et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. The Journal of cell biology. 1997. PMID 9105051. DOI: 10.1083/jcb.137.1.231. Access: full_text_partial. Study: PMID9105051.

41. Ricca BL, Venugopalan G, Furuta S et al. Transient external force induces phenotypic reversion of malignant epithelial structures via nitric oxide signaling. eLife. 2018. PMID 29560858. DOI: 10.7554/eLife.26161. Access: abstract_metadata. Study: PMID29560858.

42. Sandal T, Valyi-Nagy K, Spencer VA et al. Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme. The American journal of pathology. 2007. PMID 17456778. DOI: 10.2353/ajpath.2007.060922. Access: abstract_metadata. Study: PMID17456778.

43. Parikh AP, Curtis RE, Kuhn I et al. Network analysis of breast cancer progression and reversal using a tree-evolving network algorithm. PLoS computational biology. 2014. PMID 25057922. DOI: 10.1371/journal.pcbi.1003713. Access: abstract_metadata. Study: PMID25057922.

44. Thomsen MK, Ambroisine L, Wynn S et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer research. 2010. PMID 20103652. DOI: 10.1158/0008-5472.CAN-09-2370. Access: abstract_metadata. Study: PMID20103652.

45. Hu M, Shivdasani RA et al. Overlapping gene expression in fetal mouse intestine development and human colorectal cancer. Cancer research. 2005. PMID 16204040. DOI: 10.1158/0008-5472.CAN-05-0700. Access: abstract_metadata. Study: PMID16204040.

46. Schaeffer EM, Marchionni L, Huang Z et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008. PMID 18794802. DOI: 10.1038/onc.2008.327. Access: abstract_metadata. Study: PMID18794802.

47. Prummel KD, Crowell HL, Nieuwenhuize S et al. Hand2 delineates mesothelium progenitors and is reactivated in mesothelioma. Nature communications. 2022. PMID 35354817. DOI: 10.1038/s41467-022-29311-7. Access: abstract_metadata. Study: PMID35354817.

48. Miao Q, Hill MC, Chen F et al. SOX11 and SOX4 drive the reactivation of an embryonic gene program during murine wound repair. Nature communications. 2019. PMID 31492871. DOI: 10.1038/s41467-019-11880-9. Access: abstract_metadata. Study: PMID31492871.

49. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine. 2012. PMID 22397650. DOI: 10.1056/NEJMoa1113205. Access: abstract_metadata. Study: PMID22397650.

50. Frankell AM, Dietzen M, Al Bakir M et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023. PMID 37046096. DOI: 10.1038/s41586-023-05783-5. Access: abstract_metadata. Study: PMID37046096.

51. Kim TM, Jung SH, An CH et al. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. PMID 25979483. DOI: 10.1158/1078-0432.CCR-14-2413. Access: abstract_metadata. Study: PMID25979483.

52. Kang M, Na HY, Ahn S et al. Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors. eLife. 2022. PMID 36476508. DOI: 10.7554/eLife.78636. Access: abstract_metadata. Study: PMID36476508.

53. Chen G, Zhu W, Liu Y et al. The clonal heterogeneity of colon cancer with liver metastases. Journal of gastroenterology. 2023. PMID 37042990. DOI: 10.1007/s00535-023-01989-6. Access: abstract_metadata. Study: PMID37042990.

54. Tasdogan A, Faubert B, Ramesh V et al. Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature. 2020. PMID 31853067. DOI: 10.1038/s41586-019-1847-2. Access: abstract_metadata. Study: PMID31853067.

55. Vlashi E, Lagadec C, Vergnes L et al. Metabolic differences in breast cancer stem cells and differentiated progeny. Breast cancer research and treatment. 2014. PMID 25007966. DOI: 10.1007/s10549-014-3051-2. Access: abstract_metadata. Study: PMID25007966.

56. Rodríguez-Enríquez S, Torres-Márquez ME, Moreno-Sánchez R et al. Substrate oxidation and ATP supply in AS-30D hepatoma cells. Archives of biochemistry and biophysics. 2000. PMID 10683245. DOI: 10.1006/abbi.1999.1582. Access: abstract_metadata. Study: PMID10683245.

57. Spehalski EI, Lee JA, Peters C et al. The Quiescent Metabolic Phenotype of Glioma Stem Cells. Journal of proteomics & bioinformatics. 2019. PMID 32153327. DOI: 10.35248/0974-276x.19.12.502. Access: abstract_metadata. Study: PMID32153327.

58. Nguyen TTT, Zhang Y, Shang E et al. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. The Journal of clinical investigation. 2020. PMID 32315286. DOI: 10.1172/JCI129049. Access: abstract_metadata. Study: PMID32315286.

59. Vangapandu HV, Havranek O, Ayres ML et al. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Molecular cancer research : MCR. 2017. PMID 28835371. DOI: 10.1158/1541-7786.MCR-17-0026. Access: abstract_metadata. Study: PMID28835371.

Source-specific evidence cards

[1] Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors.

Shows: Seven TCGA tumor types, 3473 tumors/386 normals and 17318 aged genes show UC-biased expression and disrupted UC-MC coexpression; twelve hub regulators are proposed.

Does not show: Both normal and tumor tissue co-regulate ancient processes; not all UC processes rise. Bulk growth/composition and shared orthology assignments remain; no ancestral-program reconstitution.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Publisher HTML paragraphs:paragraph 25, 0:Publisher HTML paragraphs:paragraph 34, 0:Publisher HTML paragraphs:paragraph 42, 0:Publisher HTML paragraphs:paragraph 44, 0:Publisher HTML paragraphs:paragraph 49, 0:Publisher HTML paragraphs:paragraph 50. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[2] Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer.

Shows: Thirty solid cancer types connect mutation/CNA strata to UC-MC regulatory links; 364 Avana cell-line CRISPR screens and 250-drug data inform dependency/response associations.

Does not show: There is genuine single-gene perturbation data, but no selective unified ancestral network subtraction/rescue or endogenous in vivo program dependency; pooled regulator contrasts are not randomized installation.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 3:Materials and methods:paragraph 0, 3:Materials and methods:paragraph 1, 3:Materials and methods:paragraph 11, 3:Materials and methods:paragraph 12, 3:Materials and methods:paragraph 16, 3:Materials and methods:paragraph 25, 3:Materials and methods:paragraph 27. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[3] Disruption of metazoan gene regulatory networks in cancer alters the balance of co-expression between genes of unicellular and multicellular origins.

Shows: 31 cancer types and 16 matched-normal cohorts show novel mixed UC-MC WGCNA modules, CNA associations and grade/stage differences.

Does not show: Coexpression is not directed regulation; novel combinations argue against a simply restored intact network but do not disprove every partial-atavism definition. LGG/GBM class contrasts are not observed individual progression.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph 2, 1:Results:paragraph 3, 1:Results:paragraph 9, 1:Results:paragraph 12, 1:Results:paragraph 24, 1:Results:paragraph 26, 1:Results:paragraph 31. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[4] Tumor malignancy is engaged to prokaryotic homolog toolbox.

Shows: Original homology analysis identifies a prokaryotic metabolic toolbox among cancer-related human proteins.

Does not show: Conserved protein ancestry does not specify a preserved ancestral regulatory program or its causal role in tumors.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[5] The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction.

Shows: Whole-genome-duplication analysis of 1474 genes and cancer proteomics finds ancient and later placentation/cancer-testis enrichments.

Does not show: Mixed evolutionary origins and network annotation are compatible with selective reuse; neither causal program execution nor uniformly pre-metazoan identity follows.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[6] Phylostratigraphic bias creates spurious patterns of genome evolution.

Shows: Simulations show homology-detection error can bias inferred gene ages and expression-age trends.

Does not show: Synthetic detection bias does not show all cancer age patterns are artifacts; linked erratum PMID27738272 details were not accessible for examination.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID27738272. Subclaims: SC1.

[7] Further Simulations and Analyses Demonstrate Open Problems of Phylostratigraphy.

Shows: Further simulations and empirical-method assessment identify systematic phylostratigraphic errors.

Does not show: A disputed methodological result is not direct tumor causality evidence; robustness should be tested on the actual cancer gene sets.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[8] No Evidence for Phylostratigraphic Bias Impacting Inferences on Patterns of Gene Emergence and Evolution.

Shows: Reanalysis argues reported patterns withstand estimated BLAST false-negative rates of 11–15 percent.

Does not show: Methodological rebuttal is retained; persistence of a trend does not establish an ancestral driver, and cancer-specific proliferation controls are separate.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[9] Toward Reducing Phylostratigraphic Errors and Biases.

Shows: Alternative homology tools and error-prediction benchmarks fail to eliminate age-estimation bias; removal can erase or reverse tested trends.

Does not show: Results concern tested benchmarks, not a definitive refutation of every tumor phylostratigraphic association.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[10] Creation of human tumour cells with defined genetic elements.

Shows: Defined hTERT, SV40 early-region and RAS expression historically transformed human cells.

Does not show: 2026 Expression of Concern PMID41986727 concerns possible duplicated Fig 1b bands with unavailable raw data; editors retain other support. Kept as examined historical context, excluded from load-bearing positive adjudication.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ExpressionOfConcernIn: PMID41986727. Subclaims: SC3.

[11] Enumeration of the simian virus 40 early region elements necessary for human cell transformation.

Shows: SV40 elements disrupting pRB, p53 and PP2A cooperate with telomerase/RAS in human transformation.

Does not show: Engineered viral/cell-line model and shared Hahn platform; linked erratum has no supplied PMID and unexamined details. Constraint disruption does not distinguish flexible partial atavism by itself.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied. Subclaims: SC2, SC3.

[12] Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation.

Shows: Stepwise p53/INK4A/RAS/hTERT manipulations produce transformation-associated expression shifts.

Does not show: Installed elements and signatures do not isolate an ancestral network; engineered fibroblasts cannot establish general human initiation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[13] Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis.

Shows: Conditional K-RASG12D expression induces tumors in basal epithelium within 10–20 days.

Does not show: Forced expression proves regulator capability in that tissue, not the absence of all downstream evolutionary reuse.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[14] Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.

Shows: Defined elements transform FTSEC, including viral-free p53/CDK4/PP2A changes with hTERT/MYC.

Does not show: Cultured/xenografted installation is bounded; does not reconstruct or subtract a coherent ancestral program.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[15] PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.

Shows: PAX3-FOXO1/MYCN supports tumor initiation/maintenance; withdrawal regresses tumors but some recur fusion independently.

Does not show: Immortalized xenograft context; recurrence demonstrates plasticity rather than universal addiction or a universal ancestral route.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[16] Reversible tumorigenesis by MYC in hematopoietic lineages.

Shows: Switching MYC off regresses hematopoietic tumors with apoptosis/differentiation.

Does not show: Conditional transgene model; MYC necessity here does not logically exclude a required downstream ancestral module.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[17] Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

Shows: Brief MYC inactivation permits sustained differentiation; reactivation induces apoptosis in this model.

Does not show: Tissue-specific response differs from other MYC systems; no whole ancestral-network test.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[18] MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

Shows: MYC withdrawal produces differentiated dormant tumor-derived liver/biliary cells; reactivation restores tumors.

Does not show: Dormancy and reactivation differ from irreversible osteosarcoma reversion; conditional model not broad human primacy.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[19] Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.

Shows: Brief MYC shutdown is insufficient for durable islet/skin reversion, with recurrence influenced by Bcl-xL/context.

Does not show: A context boundary for regulator dependence, not proof of a single ancient fallback route.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[20] Reversible lymphomagenesis in conditionally c-MYC expressing mice.

Shows: MYC-transgene withdrawal regresses lymphoma; genomic instability and transgene-related selection accompany recurrence.

Does not show: Related MYC platforms are not independent biological replications for each paper; selection does not prove program ancestry.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[21] Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.

Shows: Recurrent tumors restore MYC signaling through tTA mutation/endogenous MYC/Notch, with MYC knockdown dependency.

Does not show: Restoration through alternative routes supports selected dependency, not universal MYC necessity or ancestral-program independence.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[22] Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

Shows: KRAS maintains pancreatic tumors and controls anabolic glucose/nonoxidative PPP use.

Does not show: Conditional oncogene setting; metabolic reprogramming is not a measured evolutionary sequence.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[23] Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Shows: After KRAS withdrawal, residual cells show respiratory dependence, poor glycolytic compensation and oligomycin-sensitive sphere/regrowth readouts; one of four treated animals remained relapse-free beyond 60 days.

Does not show: Selected model, pleiotropic drug and small in vivo arm; correction PMID41951747 (2026) lists corrected Fig 4a but full notice was unavailable. Not load-bearing alone or fully current figure audit.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 2:Main text:paragraph 1, 2:Main text:paragraph 3, 2:Main text:paragraph 6, 2:Main text:paragraph 7, 2:Main text:paragraph 10, 2:Main text:paragraph 16. No complete-paper or supplement audit claimed. ErratumIn: PMID41951747. Subclaims: SC3, SC4.

[24] Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.

Shows: YAP1/TEAD2/E2F can bypass KRAS dependence in recurrent pancreatic tumors.

Does not show: 2019 correction PMID31730860 replaces a wrong GFP image in Fig 4C; independent quantified graphs reportedly unchanged. Shared inducible platform and corrected image limit independence.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID31730860. Subclaims: SC2, SC3.

[25] Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.

Shows: KRAS ablation kills whereas MEK inhibition is cytostatic; RTK/PI3K compensation motivates combinations.

Does not show: Genetic removal and incomplete downstream pharmacology differ; effects do not establish ancestor-network necessity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[26] Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.

Shows: KRAS-associated GOT1 glutamine/redox pathway supports cultured growth and tumor assays.

Does not show: Culture/environment and redox pleiotropy; linked erratum details unavailable. Do not treat as universal metabolic dependency.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied. Subclaims: SC3, SC4.

[27] Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context.

Shows: GOT2 loss impairs cultured redox/growth but does not impair tested xenograft/autochthonous tumors; CAF pyruvate rescues culture.

Does not show: In vivo failure of pyruvate blocking to sensitize shows additional compensation; null is context-specific, not no metabolic causality.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[28] Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.

Shows: KRAS/MAPK/MYC regulates RPIA and nucleotide PPP; intervention affects differential KRAS-sensitive/resistant growth.

Does not show: Pathway-specific selected dependencies do not imply ordered historical metabolic regression.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[29] Metabolic Heterogeneity in Human Lung Tumors.

Shows: Nine NSCLC patients show glycolytic and TCA labeling with perfusion heterogeneity; NMR positional labeling and relative TCA modeling support glucose oxidation.

Does not show: Relative labeling/flux fits are not absolute ATP partitioning; circulating lactate and tissue composition confound simple cellular flux inference.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph 3, 1:RESULTS:paragraph 5, 1:RESULTS:paragraph 7, 1:RESULTS:paragraph 8, 1:RESULTS:paragraph 11. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[30] Lactate Metabolism in Human Lung Tumors.

Shows: Thirty glucose/five lactate-infused lung-cancer patients show lactate oxidation; MCT1 deletion removes lactate labeling in HCC15 xenografts.

Does not show: Model cannot quantitatively determine net lactate flow; labeled lactate enters other pools. MCT1 knockout preserves culture doubling time: substrate uptake is not demonstrated growth necessity.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph 2, 1:Results:paragraph 7, 1:Results:paragraph 9, 1:Results:paragraph 10, 1:Results:paragraph 15, 1:Results:paragraph 16. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[31] In vivo isotope tracing reveals a requirement for the electron transport chain in glucose and glutamine metabolism by tumors.

Shows: IACS complex-I inhibition reduces glucose/lactate TCA contributions and increases glutamine; yeast NDI1 NADH-oxidation rescue normalizes relevant labeling.

Does not show: TCA labeling alone does not measure ETC before perturbation; selective model rescue does not establish a universal tumor respiratory fraction.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[32] Isotope tracing reveals glycolysis and oxidative metabolism in childhood tumors of multiple histologies.

Shows: 23 tumors from 22 children show glycolytic/TCA glucose metabolism, with PDH predominant in the studied set.

Does not show: Restricted diagnoses and intraoperative infusion; labeling does not establish evolutionary ordering or absolute ATP.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[33] Does Tumor FDG-PET Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer?

Shows: 52 untreated NSCLC tumors show FDG avidity related to proliferation/alternative substrate use rather than a simple glucose-label glycolysis relation.

Does not show: FDG trapping and isotope enrichment test different processes; no direct whole-program perturbation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[34] Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer.

Shows: RAS-driven lung tumors require pyruvate oxidation in vivo and use less glutamine than cultured counterparts.

Does not show: Model-specific endogenous dependence and culture mismatch; not a universal lung/metastatic metabolism claim.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[35] Differential substrate use in EGF- and oncogenic KRAS-stimulated human mammary epithelial cells.

Shows: EGF-versus-KRASG12V proliferation matching explains most metabolic shifts in immortalized 184A1 cells; several KRAS-associated fluxes are lower at matched growth.

Does not show: Growth matching is a useful rival control, not direct validation of all TCGA gene-age associations or intact normal tissue physiology.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph 0, 1:Results:paragraph 1, 1:Results:paragraph 10, 1:Results:paragraph 11, 1:Results:paragraph 12. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[36] Increased demand for NAD+ relative to ATP drives aerobic glycolysis.

Shows: PDH activation limits growth through NADH accumulation; uncoupling/ATP hydrolysis can restore NAD balance and proliferation.

Does not show: Aerobic glycolysis can serve redox demands rather than respiratory absence; culture manipulations do not establish whole-tumor universality.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[37] Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer.

Shows: Tumors show glycolysis, oxidative PPP-derived ribose and TCA amino-acid contributions, with lactate exchange differing from lung tumors.

Does not show: Tumor-type heterogeneity rather than a longitudinal evolutionary series; labels are not absolute ATP fractions.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[38] The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Shows: Flux, protein synthesis and cell-size comparisons relate metabolism to proliferation across NCI60.

Does not show: Cell-line panel/compositional scaling cannot separate all tissue/genotype effects or infer an ancestral network.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[39] Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment.

Shows: ERBB2/EGFR/PI3K restores detached-cell glucose/PPP support; antioxidant rescue enables fatty-acid oxidation without restoring glucose uptake.

Does not show: Context/pleiotropy and culture assays; survival rescue is not coherent ancient-program reconstitution.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[40] Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies.

Shows: Function-blocking beta1-integrin antibodies/Fab revert malignant 3D phenotypes; washout restores malignancy, and brief pretreatment lowers xenograft nodules.

Does not show: Reversible single-line tissue signaling context; not universal genotype independence or reversion of all malignancy.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph 5, 1:Results:paragraph 6, 1:Results:paragraph 7. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[41] Transient external force induces phenotypic reversion of malignant epithelial structures via nitric oxide signaling.

Shows: Brief compression yields more normal acini with NO-dependent response.

Does not show: Physical context and selected 3D readouts, not endogenous in vivo cancer eradication or ancestry-specific perturbation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[42] Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme.

Shows: cAMP/PI3K/fibronectin interventions alter malignant organization and chromatin accessibility.

Does not show: Related HMT model platform; pleiotropic reversion does not establish restoration of an intact ancestral or metazoan network.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[43] Network analysis of breast cancer progression and reversal using a tree-evolving network algorithm.

Shows: Tree-based network reconstruction identifies differing routes and compensations in reverted HMT phenotypes.

Does not show: Same series/model as prior 3D studies, with inferred edges rather than independent endogenous causal replication.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[44] SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation.

Shows: SOX9 boosts proliferation without hyperplasia alone, enhances Pten-associated PIN and is attenuated by knockout.

Does not show: A metazoan developmental pathway can contribute without sufficiency; context-specific genetic interaction.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[45] Overlapping gene expression in fetal mouse intestine development and human colorectal cancer.

Shows: Colon cancers share 8–19 percent of fetal intestinal signatures compared with 1–6 percent in other tissues.

Does not show: Developmental lineage similarity is not pre-metazoan program identity or causal dependency.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[46] Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer.

Shows: Androgen-induced embryonic prostate programs are enriched in lethal prostate tumors.

Does not show: Metazoan lineage-program overlap and association; no selective driver subtraction/rescue.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[47] Hand2 delineates mesothelium progenitors and is reactivated in mesothelioma.

Shows: Hand2 loss affects mesothelial development; reactivation is observed in mesothelioma.

Does not show: Developmental loss-of-function is not tumor Hand2 necessity, and reactivation is of a later multicellular program.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[48] SOX11 and SOX4 drive the reactivation of an embryonic gene program during murine wound repair.

Shows: SOX11/4 embryonic-state induction and knockout influence normal repair through targets including fascin.

Does not show: Physiological embryonic reuse can occur without cancer; normal repair comparator is not tumor-program disproof.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[49] Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Shows: Four renal tumors show branched regional evolution with 63–69 percent of somatic alterations not shared across regions.

Does not show: Heterogeneity does not exclude a conserved underlying program; linked erratum details unavailable and no ancestral-state perturbation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied. Subclaims: SC2, SC3.

[50] The evolution of lung cancer and impact of subclonal selection in TRACERx.

Shows: TRACERx 1644 regions from 421 patients documents branching, whole-genome duplication and subclonal selection associated with relapse.

Does not show: 2024 correction swaps death/censor symbols in Fig 1; original notice examined. Clonal selection is not itself proof against all ancient cellular modules.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID38965439. Subclaims: SC2, SC3.

[51] Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity.

Shows: Five primary/liver-metastasis cases show branched genetic heterogeneity.

Does not show: Small observational phylogeny cannot identify a specific regulatory mechanism or exclude a shared function.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[52] Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors.

Shows: Eleven cases show early branching among precursor, primary and metastatic lesions.

Does not show: Timing/branching inference is not direct ancestor-program activity or causal removal.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[53] The clonal heterogeneity of colon cancer with liver metastases.

Shows: Thirty samples from eight patients exhibit parallel, linear and branched routes.

Does not show: Multiple routes constrain a rigid trajectory but are not direct tests of all atavism variants.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[54] Metabolic heterogeneity confers differences in melanoma metastatic potential.

Shows: MCT1 perturbation reduces metastasis without equivalent primary-growth effects; antioxidants rescue selected readouts.

Does not show: Relapse/metastatic metabolism differs from primary growth and culture uptake; transplantation context limits generality.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[55] Metabolic differences in breast cancer stem cells and differentiated progeny.

Shows: Stem-like cells show greater oxidative capacity and less lactate than differentiated counterparts; irradiation alters states.

Does not show: Marker/culture selection does not establish a stable endogenous hierarchy or ordered backward evolution.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[56] Substrate oxidation and ATP supply in AS-30D hepatoma cells.

Shows: AS30D hepatoma respiration/oligomycin analyses estimate predominantly oxidative ATP production.

Does not show: Single cell model and ATP estimation assumptions; does not quantify all human cancers.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[57] The Quiescent Metabolic Phenotype of Glioma Stem Cells.

Shows: Quiescent glioma stem-like populations have low glycolytic and oxidative rates with metabolic heterogeneity after irradiation.

Does not show: Cultured selection and state-specific output, not generalized tumor-wide respiratory failure or a serial evolutionary order.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[58] HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models.

Shows: HDAC inhibition lowers MYC and raises PGC1/PPAR-linked FAO/OXPHOS; combined FAO/HDAC intervention improves tested tumor-model survival.

Does not show: Drug pleiotropy and selected settings; induced forward adaptation fits metabolic plasticity without ancestry-specific identification.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[59] B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.

Shows: 45-patient CLL cohort shows variable respiration linked to prognosis; BCR/PI3K perturbation reduces OCR and ECAR.

Does not show: Ex vivo signaling and association do not establish universal respiratory dependency or evolutionary ordering.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• SHA256.txt
• adversarial-findings.json
• cancer-atavism.review.md
• cancer-atavism.scorecard.json
• codex-correction-provenance.json
• consensus-addendum.md
• consensus-validation.json
• edition-approval-audit.json
• reader-summary.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt

Sources: 59 · load-bearing claims: 64 · verified: 64 · unverified: 0 · contradicted: 0 · schema 5.3